Kedu ihe Bachem siri ike H1 2026 na Nlaghachi Ogologo Afọ iri pụtara maka ahịa CDMO Peptide
Kedu mgbe Bachem Holdings AG na-ebipụta akụkọ ego H1 2026 akụkọ ego, Ọnụọgụ ndị ahụ nyere ihe karịrị mmelite nke otu ụzọ n'ụzọ anọ maka ndị nyocha nha nhata. Site na ire otu na-erute CHF 326.4 nde (+7.3% uto na ego mpaghara) yana ire ngo ụlọ ọgwụ na ngalaba mmepe CMC ya na-arị elu +39.5% na ego mpaghara gaa na CHF 167.5 nde, ụlọ ọrụ ahụ gosipụtara nnukwu ọsọ nke ọchịchọ biopharmaceutical ugbu a. Nkwado site na ntụzịaka mmụba ego n'ịkwalite ego na-adị kwa afọ gbadara ruo 35%-40% yana atụmatụ mmefu ego afọ zuru oke. (CAPEX) Mgbanwe nke ọnụ ahịa nke CHF 350 nde na CHF 400 nde, Usoro ego nke Bachem na-eje ozi dị ka onye nnọchi anya akụ na ụba zuru ụwa ọnụ peptide CDMO ahịa.
Maka biopharma C-suites, Ndị isi nlekọta ahụike, na ndị isi nke Chemistry, Imepụta, na njikwa (CMC), Ịgụ nsonaazụ ego ndị a chọrọ usoro ntụgharị asụsụ. Bachem na-alaghachi azụ n'ime afọ iri nke na-aga n'ihu na nnukwu mgbasawanye ihe owuwu na-aga n'ihu - dị ka ọrụ azụmahịa nke Ụlọ K na Bubendorf na mmepe greenfield na Sisslerfeld - na-akọwapụta eziokwu nhazi.: isi obodo zuru ụwa ọnụ na-agbakọ gburugburu multi-ton azụmahịa blockbusters na ọrịa metabolic, glucagon-dị ka peptide-1 (GLP-1) agonists anabata, na oligonucleotide therapeutics.
Agbanyeghị, Nleta isi obodo mega a na-ebute nsonaazụ arụmọrụ n'ofe usoro ọkọnọ. Dị ka Tier-1 ndị na-emepụta nkwekọrịta na-etinye mpịakọta reactor na nkwekọrịta ọkọnọ azụmahịa ọtụtụ afọ, CDMO nke etiti ọkwa na-eche ngbanwe oke oke ihu, ebe biotech na pharma R&Ndị otu D na-ezute oge ndu na-arị elu na-ebunye adịghị ike maka pipeline ụlọ ọgwụ nke abụọ. Ịtụle usoro ego ndị a na-enye nghọta dị mkpa na nnweta ego, leverage ọnụahịa, na atụmatụ inyefe ihe nhụsianya n'okirikiri ala peptide zuru ụwa ọnụ.
Ịgụ akwụkwọ Bachem's Balance dị ka onye nnọchi anya ụlọ ọrụ: Ike isi obodo na oke ọnụ ọgụgụ
Iji ghọta ihe kpatara ya peptide CDMO ahịa na-enwe ike tightness na-enwetụbeghị ụdị ya, onye ga-enyocha usoro nhazi nguzozi nke onye isi ahịa ya. Ịrụ ụlọ na iru eru maka akụrụngwa nrụpụta peptide nke azụmahịa abụrụla otu n'ime mbọ kacha akpata ego n'ichepụta ọgwụ..
Na ọkara mbụ nke 2026 naanị ya, Bachem etinye ego na CHF 148.4 nde na akụrụngwa nrụpụta ụwa. Ebe ego a na-enweta na mmepe CMC gbasaara nke ukwuu n'ihi mmemme usoro ụlọ ọgwụ n'oge oge, Ahịa API azụmaahịa gbadara nwa oge gaa na CHF 133.0 nde (-19.3% na ego obodo), na-egosipụta ngbanwe nhazi oge tupu iwulite ọnụ ọgụgụ azụmahịa zuru oke nke K. N'otu oge, Oke EBITDA nke Bachem tụgharịrị gaa 25.4% (CHF 82.8 nde) atụlere yana 29.1% n'oge tupu afọ.
Ego & Ihe ngosi arụmọrụ (Bachem H1 2026 vs. Mmetụta proxy ụlọ ọrụ)
Metric H1 2026 Akwupụtara ntụgharị asụsụ Uru Ahịa & Pụtara arụmọrụ
Otu Net Sales CHF 326.4M (+7.3% LC) Mgbasawanye ahịrị elu na-adịgide adịgide n'ofe ụlọ ọgwụ & TIDES azụmahịa.
Ahịa Mmepe CMC CHF 167.5M (+39.5% LC) Ọrụ nnwale ụlọ ọgwụ n'oge na-anabata ikike CDMO pụrụ iche.
H1 CAPEX Investment CHF 148.4M nnukwu ego tupu ebugo chọrọ maka nnukwu ọnụ ụlọ SPPS.
FY2026 Atụmatụ CAPEX CHF 350M - 400M na-ewepụta ihe mgbochi narị nde dollar na ntinye Tier-1.
Ọnụ ego nke EBITDA 25.4% (vs. 29.1% tupu) Ọnụ ego a kapịrị ọnụ yana ụgwọ ntozu akụrụngwa na-agbakọ oke nso nso.
Mkpịsị akụkụ EBITDA nwa oge a na-ekpughe eziokwu bụ isi gbasara Synthesis Solid-Phase Peptide nke ọgbara ọhụrụ. (SPSS): Ọnụ ego a kapịrị ọnụ nke ịka elu dị nnukwu. Tupu enwere ike ịwepụta otu batch azụmahịa nke amino acid peptide dị mgbagwoju anya 30 ruo 40, ndị na-emepụta ga-etinyerịrị afọ nke mbelata ego, ntozu ihe owuwu, nkwado gburugburu ebe obibi, na ndị ọkachamara teknuzu ọrụ n'elu.
Dị ka ọ pụtara na nyocha mgbasawanye ikike TIIDES zuru ụwa ọnụ, Enwetaghị ego n'ime ngalaba CDMO anaghịzi ekesa nke ọma. Ọ na-aga nke ọma na ndị na-emepụta ihe nwere ike ịme ihe nrụpụta ọtụtụ puku tọn kwa afọ. Maka ụlọ ọrụ biopharma etiti na apụta, ike isi obodo a na-emepụta usoro ahịa nke abụọ: CDMO nke Tier-1 na-ebuwanye ibu maka nkwekọrịta azụmahịa mega-olu, na-ahapụ n'etiti olu na mmalite usoro ụlọ ọgwụ na-asọ mpi maka obere oge reactor na-agbanwe agbanwe.
Na-ewuli eriri ọkpọnye ndị na-eweta ihe: Ihe ndị dị n'elu iji mejupụta ime ụlọ dị ọcha
Mgbe isi akụkọ ụlọ ọrụ na-elekwasị anya na olu reactor, Ndị isi CMC nwere ahụmahụ ghọtara nke ahụ peptide n'ichepụta ikike bottlenecks na-agbatị usoro ahụ dum, site na ngwakọta kemịkalụ akụrụngwa ruo na ikewapụ ikpeazụ.
Nkwanye kemịkalụ elu → Synthesis Reactor Suites → Nrụcha ala → Lyophilization & Ime ụlọ ọcha
(Fmoc-amino acid / Resins) (SPSS / LPPS / gbaa ụka) (Prep-HPLC / Mkpesa) (Klas 100 Nnọpụ iche & CoA)
Ntugharị igodo: Ihe mgbochi ikike izizi na nrụpụta peptide adịchaghị ejedebe na olu reactor. Mgbasa ozi kọlụm nkwado HPLC nke mgbada, ihe mgbaze mgbake usoro, na Klas 100 Ụlọ dịpụrụ adịpụ nke ime ụlọ dị ọcha na-anọchite anya mkpọmkpọ mkpọ nke mbụ maka ihe ọkwa ụlọ ọgwụ.
1. Ntụnye ihe akụrụngwa akụrụngwa dị n'elu
Ngwakọta peptides dị mgbagwoju anya na-adabere na ntọala akụrụngwa akụrụngwa gbadoro anya nke ukwuu. gafere 85% nke Global Fmoc- na amino acid nke Boc chedoro, specialized functionalized resins (dị ka Wang, Rink Amide, na chlororityl resins), na elu-arụmọrụ njikọ reagents (Ntụpụ ụkwụ, PyBOP, HOBt) sitere na ọnụ ọgụgụ dị nta nke ndị na-emepụta kemịkal pụrụ iche. Mgbe mmemme GLP-1 bụ isi azụmaahịa na-eri ọtụtụ narị metrik tọn akụrụngwa, oge ndu maka amino acid omenala ma ọ bụ ọrụ resin pụrụ iche nwere ike gbatịa site na 6 ka 12 ọnwa, ịmepụta ihe egwu oge ozugbo maka ọrụ ụlọ ọgwụ onwe ha.
2. Upstream Reactor na-eduga Oge
Igwe ọkụ SPPS dị n'ọrụ mmepụta ihe (>1,000 lita) chọrọ mgbagwoju mgbali ụgbọ injinia, usoro nnyefe ihe mgbaze na-akpaghị aka, na ihe mgbawa pụrụ iche (ATEX) nhazi ụlọ dị ọcha. Oge ndu maka inweta na inye ọrụ nnukwu igwe reactors SPPS dị ugbu a n'etiti 18 na 36 ọnwa. Ọbụlagodi mgbe echekwabara isi obodo zuru oke, Nrụnye akụrụngwa anụ ahụ na ntozu usoro na-etinye oke ọsọ ọsọ na ngwa ngwa ngwa ngwa zuru ụwa ọnụ nwere ike gbasaa.
3. Ọcha nke mgbada na mgbanwe mgbanwe
Nhazi ala na-anọgide na-abụ nnukwu nsogbu teknụzụ dị na mwepu peptide. Na-esochi mgbawa siri ike na mmiri ozuzo peptide crude, ịdị ọcha chọrọ nkwado ndabere-na-agbanwe Chromatography Liquid Liquid (HPLC). Ihe mgbochi isi gụnyere:
- Mkpebi Chromatographic (R ₛ): Na-ekewa usoro nhichapụ nwere njikọ chiri anya (dị ka n-1 ma ọ bụ n+1 adịghị ọcha nke mkpọpu na-akpata site na njikọ ezughị ezu) na diastereomers na-achọ ogidi dayameta buru ibu juputara na silica pụrụ iche C18 ma ọ bụ C8 tụgharịa.. Ọmụmaatụ, na ogologo yinye GLP-1 analogs (>30 foduru), nchịkọta hydrophobic n'oge nbudata nwere ike ibelata ọnụ ọgụgụ efere kọlụm nke ukwuu, chọrọ gradients organic modifier ahaziri iji dozie isomers na-emekọ ihe ọnụ.
- mgbake mgbake: Nchacha ọtụtụ-ton chọrọ oke nke acetonitrile (ACN) na trifluoroacetic acid (TFA), na-achọ ka ụlọ ọrụ mgbake mgbake nkeji iji nọgide na-akwado gburugburu ebe obibi na njikwa ụgwọ ọrụ.
- Ntugharị Counterion: Ịtụgharị trifluoroacetate salts ka ọ bụrụ acetate ma ọ bụ chloride nke a na-anabata nke ọma na-achọ usoro chromatography mgbanwe nke abụọ., na-agbakwụnye oge usoro na enwere mfu mkpụrụ. Peptide Synthesis
4. Lyophilization na klas 100 Mwepu ime ụlọ dị ọcha
Nnukwu peptide na-arụ ọrụ ọgwụ (API) chọrọ nnukwu ihicha-ihicha (lyophilization) ikike iji guzobe nkwụsi ike steeti ogologo oge. Ọzọkwa, maka parenteral formulations, Ijikwa nnukwu na nkwakọ ga-emerịrị na klaasị ekwenyesiri ike 100 (ISO 5) gburugburu ime ụlọ dị ọcha iji kpochapụ mmetọ bioburden na endotoxin. Ụlọ ọrụ enweghị klaasị zuru oke 100 Ime ụlọ dị ọcha na-adịghị ọcha na-eche nnukwu nsogbu iwu ihu mgbe a na-agbanwe ihe sitere na njikọ ụlọ nyocha gaa n'imecha ụlọ ọgwụ..
Ike ịnye ọnụahịa na mkpọchi nkwekọrịta: Iwu ọhụrụ nke itinye aka
Enweghị ahaghị nhata n'etiti mkpa ọgwụgwọ na-arị elu yana mkpachi isi ego agbanyela nrịanrịa ọnụ ahịa ahịa n'ebe ndị nrụpụta nkwekọrịta guzosiri ike..
Ọnụ ahịa nrụpụta nkwekọrịta maka oke GLP-1 peptide API abawanyela site na 25% ka 40% gafee isi CDMO kemgbe 2023. N'ofe mbute onu ahia nke mbu, Ọdịdị nke CDMO nkwekọrịta nwere
Glp na onye nrụpụta Peptides Ihe Nlereanya Nkwekọrịta Parameter Legacy CDMO (Tupu 2023) Ọkọlọ ahịa Ahịa ọgbara ọhụrụ (2026+)
p>Ihe Nlereanya Nkwekọrịta Parameter Legacy CDMO (Tupu 2023) Ọkọlọ ahịa Ahịa ọgbara ọhụrụ (2026+)
Ike Nkwenye Spot-ahịa & Nkwekọrịta ndoputa n'ogbe 3 ruo-5 were ma ọ bụ kwụọ ụgwọ
Nkwụnye ego ndoputa 10% - 20% aga n'ihu 40% - 50% nkwa nkwụghachi n'ihu
Anabatara ma ọ bụ wetuo ya nke ukwuu ụgwọ mbufe teknụzụ nwere ọnụ ụzọ ámá siri ike
Hazie mgbanwe mgbanwe ụbọchị 30 ruo 60 na-emegharị oge ntaramahụhụ kagbuo siri ike. & oghere ekpochi
Akụrụngwa
CDMO Tier-1 na-achọkwa nkwekọrịta ndoputa ikike afọ 3 ruo-5 yana nnukwu nkwụnye ego anaghị akwụghachi ya.. Maka nnukwu ụlọ ọrụ na-emepụta ọgwụ na-akwado site na franchise azụmahịa ọtụtụ ijeri dollar, Usoro ndị a bụ mkpuchi ọrụ anabatara. Agbanyeghị, maka ụlọ ọrụ biotech nke etiti na-agagharị ule ụlọ ọgwụ nke Oge I/II, Nkwenye ịkwụ ụgwọ ma ọ bụ ịkwụ ụgwọ na-ewebata ihe egwu akwụkwọ nguzozi anabataghị. Ụlọ ọrụ Gku Peptide
al ọnwụnwa, Nkwenye ịkwụ ụgwọ ma ọ bụ ịkwụ ụgwọ na-ewebata ihe egwu akwụkwọ nguzozi anabataghị.
Iji belata nnabata na adịghị ike arụ ọrụ, Otu ndị na-akwado ịzụ ahịa kwesịrị ịhazi ntozu ndị na-ere ahịa na ICH Q7 ntuziaka omume nrụpụta dị mma maka ngwa ọgwụ na-arụ ọrụ. Ịkwado nkwekọrịta dị mma n'oge na-eme ka CDMO nke abụọ na-agbaso ụkpụrụ iwu siri ike na-enweghị iweta mbufe teknụzụ na-agafe agafe mgbe nhazi ọkwa Tier-1 na-atụghị anya ya mere..
Mgbe ụlọ ọrụ Tier-1 nwetara mgbanwe nhazi oge ma ọ bụ weghachite suite reactor gaa na blockbuster azụmahịa., obere oru ngo na-adakarị ihe ize ndụ ịbụ onye a ga-ebupụ ụzọ. Ebe a na-eme ka ịdabere na otu, CDMO mega-oke bụ nnukwu adịghị ike arụ ọrụ maka pipeline na-abụghị blockbuster.
Mmetụta atụmatụ maka CDMO nke etiti na n'ime ụlọ R&D Otu
Ịgagharị gburugburu ahịa a chọrọ atụmatụ arụ ọrụ ahaziri ahazi dabere ma ụlọ ọrụ na-enye ọrụ CDMO ma ọ bụ na-azụta ha maka ọkpọkọ ụlọ..
Maka Mid-Tier CDMOs: Ihe dị iche iche dị mkpa
Ndị na-emepụta nkwekọrịta nke etiti enweghị ike imeri agha isi obodo megide ndị isi ahịa ahịa ijeri dollar ijeri na-etinye ego CHF 400 nde kwa afọ na ngwa ahịa SPPS. Na-agbalị ịmepụta ahaziri, Ngwakọta ngwa ahịa GLP-1 na-enweghị echekwabara nkwekọrịta iwepụta ogologo oge na-ekpughe CDMO nke etiti na mkpakọ oke oke ma ọ bụrụ na ọkọnọ ahịa na-ahazi..
Kama, CDMO n'etiti ọkwa na-aga nke ọma na-echekwa ọkwá dị elu site na nka nka pụrụ iche:
- Mgbanwe usoro mgbagwoju anya: Ịmụta kemistri siri ike, gụnyere multi-bridge disulfide cyclization, egbugbere ọnụ saịtị akọwapụtara, PEGylation, ntinye amino acid na-ekwekọghị n'okike, na akara fluorescent (>300 ọrụ iche iche otu).
- Ụzọ njikọ ngwakọ: Na-ejikọta SPPS ọdịnala yana njikọ Peptide Liquid-Phase (LPPS) mkpirisi mkpirisi ma ọ bụ gbaa ụka microbial recombinant iji bulie mkpụrụ crude maka peptides nwere ogologo ogologo. (>40 amino asịd).
- Ike ime ụlọ agile: Na-enye ngwa ngwa, Klas 100 mkpochapụ nke ime ụlọ dị ọcha maka ihe ndị na-ahụ maka usoro ahụike, na-enye ndị nkwado ohere ịgafe ahịrị ndoputa ọtụtụ afọ Tier-1.
Maka In-House Biopharma R&D Otu: Chegharịa echiche Isi mmalite & Atụmatụ echere
Maka ọgwụgwọ nke biopharma, ndị njikwa ịzụ ahịa, na R&D ndị nduzi, Ndabere otu isi iyi na Tier-1 CDMO na-anọchite anya ihe egwu dị oke egwu. Na-eme ihe dị irè peptide chain plan contingency atụmatụ chọrọ iguzobe nke ziri ezi, matriks ndị na-ere ọtụtụ ọkwa.
Isi mmalite Architecture: Tier-1 Azụmahịa vs. Agile Specialized Partner
Isi mmalite nke Tier Primary Ọrụ Mgbado Kachasị Mma Ọrụ Pipeline
Tier-1 Mega CDMOs Multi-ton azụmahịa nrụpụta blockbusters azụmahịa akwadoro (Agba III/Ahịa)
Agile Specialized CDMOs Njikọ omenala dị elu dị elu, Oge I/II nke ụlọ ọgwụ, usoro siri ike,
Klas 100 nnabata adịghị mma, mgbagwoju anya mgbanwe, na usoro ihe eji eme ihe abụọ
ngwa ngwa teknụzụ nyefe & ọnụ ọgụgụ-elu
Site na iguzobe ihe nlere anya nke nwere ike ime n'oge mmalite, ndị nkwado na-ejigide mgbanwe ọrụ zuru oke. Ebe onye mmekọ Tier-1 na-ejikwa atụmatụ nkwalite azụmahịa ogologo oge, ihe agile, onye mmekọ pụrụ iche na-ejikwa ngwa ngwa ụlọ ọgwụ, nyocha mgbanwe mgbagwoju anya, na mmepụta nkwado ndabere na mpaghara mberede.
Isi mmalite & Akwụkwọ egwu egwu: Ịkwụsị Chain Supply Resilience
Iji gbochie mmemme ụlọ ọgwụ site na mpịakọta ikike zuru oke n'ahịa, biopharma R&Ndị otu D kwesịrị ịme akwụkwọ egwuregwu nkwụghachi ụgwọ nke usoro atọ.
Nzọụkwụ 1: Ihe nchekwa ihe dị elu → Nzọụkwụ 2: Agile Dual-Sourcing Partner → Nzọụkwụ 3: Nghọta nyocha
(Tozuru oke resin/amino acid nke abụọ) (Klas 100 nyocha ụlọ ọcha) (HPLC/MS emebeghị ya & CoA)
Nzọụkwụ 1: Ngosipụta mbụ nke akụrụngwa akụrụngwa dị elu
Ekwela ka CDMO dabere na amino asịd ma ọ bụ resin ọpụrụiche tozuru etozu. Ndị na-akwado ya kwesịrị inyocha onwe ya ma dezie ndị na-eweta ụwa nke abụọ maka Fmoc-amino acid dị mkpa., njikọ reagent, na cleavage cocktails dịkarịa ala 12 ka 18 ọnwa tupu ibido pivotal clinical trial n'ichepụta.
Nzọụkwụ 2: Gwakọta Onye Mmekọ Dual-Sourcing Agile
Nkwekọrịta na otu Ngwakọta peptide omenala agbakwunyere na ikpo okwu mgbanwe na-enye mkpuchi ozugbo megide igbu oge CDMO mbụ. Mgbe ị na-enyocha ndị mmekọ ụlọ akwụkwọ pụrụ iche, R&Ndị otu D ga-enyocharịrị:
- Ịdị ọcha na Ọnụ ọgụgụ: Ikike iji wepụta ịdị ọcha dị elu ekwela nkwa (≥98%) usoro na-agbakọ n'enweghị nsogbu site na milligram-level R&D nyocha na ogbe pilot ọtụtụ kilogram.
- Gburugburu Imepụta Sterile: Ekwetara Klas 100 ụlọ nrụpụta ụlọ dị ọcha nke ultra-sterile iji kpochapụ ihe egwu mmetọ n'oge mmepe mmepụta.
- Mgbanwe Uro: Ọkachamara nka na ụzụ na-agafe 300 ụdị mgbanwe omenala, gụnyere lipidation, stapling, na enzymatic conjugation.
Nzọụkwụ 3: Manye nghọta zuru oke gbasara nyocha
Peptide Synthesis Iguzosi ike n'ezi ihe nyocha bụ enweghị mkparịta ụka mgbe a na-emefefe teknụzụ n'etiti ndị na-ebubata ndị isi na nke abụọ. N'okpuru I Q2(R1) ntụzịaka nkwado nyocha, ndị nkwado ga-achọrịrị Asambodo nyocha zuru oke (CoA) akwụkwọ maka batch ọ bụla, gụnyere:
- Ihe nyocha HPLC chromatogram dị elu na-egosi pasentị na mkpebi ịdị ọcha (Rₛ ≥ 1.5) site na adịghị ọcha mkpochapụ dị n'akụkụ.
- Nyochaa Mass Spectrometry site na Electrospray ionization (ESI-MS) ma ọ bụ Matrix-Assissted Laser Desorption/ionization (MALDI-TOF) n'izizi oke oke n'ime nkwado ppSponsors anabatara MOL mgbanwe rite uru n'aka onye mmekọ agile kwadoro elu-ọcha Peptide Synthesis peptide synthema
Maka ndụmọdụ: Na-achọ mgbe niile ka emebeghị ya, raw analytical HPLC na nnukwu ụdịdị data faịlụ n'oge CDMO tech na-enyefe. Na-adabere na Ụlọ nyocha nke Bluum Peptides Nchịkọta tebụl CoA na-enweghị akara chromatographic raw nwere ike kpuchie adịghị ọcha na-eme ka ọ daa ọdịda n'oge mmụba ụlọ ọgwụ..
data iguzosi ike n'ezi ihe gafee niile mmepe nkebi.
Maka ndụmọdụ: Na-achọ mgbe niile ka emebeghị ya, raw analytical HPLC na nnukwu ụdịdị data faịlụ n'oge CDMO tech na-enyefe. Ịdabere na nchịkọta CoA tebụl na-enweghị akara chromatographic raw nwere ike kpuchie adịghị ọcha nke na-akpata ọdịda ogbe n'oge mmụba ụlọ ọgwụ..
Ajụjụ a na-ajụkarị (FAQ)
Kedu ka ịgbasa ikike CDMO Tier-1 si emetụta oge ndu maka usoro ụlọ ọgwụ na-abụghị GLP-1?
N'ihi na CDMO Tier-1 na-ebute nkwekọrịta azụmahịa ọtụtụ ton GLP-1 iji bulie ojiji reactor., oge ndu maka omenala, Usoro ọgwụgwọ na-abụghị GLP-1 na ndị na-ebubata ngwaahịa agbatịla ọnwa 12-18.. Ndị na-akwado Biopharma nwere ike ịgafe ahịrị ndị a site na ijikọ CDMO dị n'etiti etiti pụrụ iche nke na-edobe ụlọ raara onwe ya nye maka nhazi ụlọ ọgwụ..
Kedu ihe bụ isi ihe na-arụ ọrụ mgbe ị na-eme ka peptides omenala si na milligram ruo kilogram?
N'olu bụ isi na-adịkarị ka ọsọ njikọ njikọ siri ike; ọ bụ mgbakwasa HPLC dị ọcha na ikike lyophilization. Ka ogbe nha na-abawanye, ịdị ọcha crude na-adaba ogologo oge ma ọ bụ usoro hydrophobic, na-achọ mpịakọta kọlụm nkwadebe ka ukwuu, elu mgbaze mgbake ike, na ogologo okirikiri ihicha ikuku iji nweta ịdị ọcha ebumnuche (≥ 98%).
Kedu ka biopharma R&Ndị otu D na-emejuputa ihe nlere anya ụzọ abụọ dị irè na-enweghị ịrị elu ego nkwado?
A na-enweta usoro ihe abụọ dị mma site n'ikewa ọrụ nrụpụta dabere na ọkwa mmepe na ụdị kemistri.. Ndị na-ebubata Tier-1 nke mbụ na-ejikwa olu dị elu, mmepụta API azụmahịa ahaziri ahazi, ebe ndị mmekọ pụrụiche nke abụọ tozuru oke n'isi maka inye ụlọ ọgwụ na-agba nke I/II, mgbagwoju mgbanwe usoro, na ihe nkwado ndabere mberede. Iji usoro nyocha ahaziri ahazi n'okpuru ICH Q2(R1) na-ebelata mmefu mbufe teknụzụ anaghị arụ ọrụ.
Atụmatụ Omume Strategic: Chekwaa Chain Supptide gị
Bachem siri ike H1 2026 Nsonaazụ ego na-akwado na ahịa peptide zuru ụwa ọnụ na-abanye n'oge uto na-enwetụbeghị ụdị ya na ike isi obodo.. Ọ bụ ezie na ume a na-akwado ike ọgwụgwọ na-agbasawanye nke ọgwụgwọ peptide, ọ na-egosikwa ike na-adịgide adịgide, ọzọ ọnụ, na nnukwu ụlọ ọrụ nkwekọrịta n'ichepụta gburugburu ebe obibi.
Biopharma R&Ndị otu D na ndị isi CMC enweghị ike ị nweta ụzọ nchere na ịhụ anya. Ichekwa ọnụ ọgụgụ dị egwu nke ọkpọkọ chọrọ njikwa ihe egwu nke ọma, ntozu ihe n'elu, na usoro ihe eji eme ihe abụọ.
Iji nyochaa otú onye agile, Klas 100 Onye mmekọ nke nwere asambodo ụlọ dị ọcha nwere ike igbochi pipeline gị n'ọgba aghara ahịa, kọntaktị MOL mgbanwe taa iji nyochaa ike usoro omenala, ike nyocha nyocha, ma chekwaa ikike nrụpụta ụlọ ọgwụ dị oke ọcha.
